Friday, 4 April 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 04 April 2025
News

Top drugs chase bigger markets

Posted 3 April 2025 AM

Some big names are seeking a greater population to treat at the July PBAC meeting, as PBAC gets set to consider 14 changes to listings.

BMS is seeking another couple of indications for Opdivo and Yervoy. One is for the first line treatment of microsatellite instability high or mismatch repair deficient unresectable or metastatic colorectal cancer. The other is for the first line treatment of advanced unresectable Barcelona Clinic Liver Cancer Stage A, Stage B or Stage C hepatocellular carcinoma.

To see the whole article, please login

Popular

Drugs quietly listed on the PBS
Lifeline arrives for world's top drug
TGA greenlights 17 new drug uses
Trump lets pharma off the hook
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (21)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Other (20)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home